From Financial Modeling Prep: 2025-06-04 11:00:00

PTC Therapeutics, Inc. (NASDAQ:PTCT) excels in capital efficiency with a ROIC of 31.66% and a WACC of 9.69%, resulting in a strong ROIC to WACC ratio of 3.27. In comparison, Ultragenyx Pharmaceutical Inc. (RARE) and Agios Pharmaceuticals, Inc. (AGIO) show inefficiency with negative ratios.

Amicus Therapeutics, Inc. (FOLD) leads the peer group with a remarkable ROIC of 55.32% and a WACC of 7.39%, achieving an impressive ROIC to WACC ratio of 7.49. This highlights Amicus Therapeutics’ superior ability to generate returns on invested capital compared to its competitors.



Read more at Financial Modeling Prep:: PTC Therapeutics’ Financial Performance and Capita…